We provide you with 20 years of free, institutional-grade data for MRTX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of MRTX. Explore the full financial landscape of MRTX stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2023-11-06 | 1576263 | MRTX | 10-Q | Url |
| 2023-08-08 | 1576263 | MRTX | 10-Q | Url |
| 2023-05-09 | 1576263 | MRTX | 10-Q | Url |
| 2023-02-28 | 1576263 | MRTX | 10-K | Url |
| 2022-11-08 | 1576263 | MRTX | 10-Q | Url |
| 2022-08-03 | 1576263 | MRTX | 10-Q | Url |
| 2022-05-04 | 1576263 | MRTX | 10-Q | Url |
| 2022-02-28 | 1576263 | MRTX | 10-K | Url |
| 2021-11-08 | 1576263 | MRTX | 10-Q | Url |
| 2021-08-05 | 1576263 | MRTX | 10-Q | Url |
| 2021-05-06 | 1576263 | MRTX | 10-Q | Url |
| 2021-02-25 | 1576263 | MRTX | 10-K | Url |
| 2020-11-04 | 1576263 | MRTX | 10-Q | Url |
| 2020-08-06 | 1576263 | MRTX | 10-Q | Url |
| 2020-05-07 | 1576263 | MRTX | 10-Q | Url |
| 2020-02-26 | 1576263 | MRTX | 10-K | Url |
| 2019-11-04 | 1576263 | MRTX | 10-Q | Url |
| 2019-08-05 | 1576263 | MRTX | 10-Q | Url |
| 2019-04-29 | 1576263 | MRTX | 10-Q | Url |
| 2019-02-28 | 1576263 | MRTX | 10-K | Url |
| 2018-11-06 | 1576263 | MRTX | 10-Q | Url |
| 2018-08-01 | 1576263 | MRTX | 10-Q | Url |
| 2018-05-07 | 1576263 | MRTX | 10-Q | Url |
| 2018-03-08 | 1576263 | MRTX | 10-K | Url |
| 2017-11-01 | 1576263 | MRTX | 10-Q | Url |
| 2017-08-03 | 1576263 | MRTX | 10-Q | Url |
| 2017-05-04 | 1576263 | MRTX | 10-Q | Url |
| 2017-03-09 | 1576263 | MRTX | 10-K | Url |
| 2016-11-03 | 1576263 | MRTX | 10-Q | Url |
| 2016-08-04 | 1576263 | MRTX | 10-Q | Url |
| 2016-05-05 | 1576263 | MRTX | 10-Q | Url |
| 2016-03-09 | 1576263 | MRTX | 10-K | Url |
| 2015-11-06 | 1576263 | MRTX | 10-Q | Url |
| 2015-08-06 | 1576263 | MRTX | 10-Q | Url |
| 2015-05-06 | 1576263 | MRTX | 10-Q | Url |
| 2015-03-11 | 1576263 | MRTX | 10-K | Url |
| 2014-11-10 | 1576263 | MRTX | 10-Q | Url |
| 2014-08-08 | 1576263 | MRTX | 10-Q | Url |
| 2014-05-15 | 1576263 | MRTX | 10-Q | Url |
| 2014-03-17 | 1576263 | MRTX | 10-K | Url |
| 2013-11-12 | 1576263 | MRTX | 10-Q | Url |
| 2013-10-03 | 1576263 | MRTX | S-1 | Url |
| 2013-08-13 | 1576263 | MRTX | 10-Q | Url |
Mirati Therapeutics, Inc(NASDAQ:MRTX) 
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NS...
Website: http://www.mirati.com
Founded: 1995
Full Time Employees: 111
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about MRTX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.